Free tool
FAERS Monitor: Pomalyst
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204026 or its brand name (Pomalyst, Pomalidomide). Reports on generic versions are filed under their own applications.
Reports
103,640
Serious
63,661
61% of reports
Hospitalization
27,668
Death reported
14,174
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma8,169
- death7,797
- fatigue7,599
- pneumonia6,387
- off label use4,625
- diarrhoea3,966
- white blood cell count decreased3,709
- neutropenia3,391
- rash3,107
- dyspnoea2,887
- asthenia2,718
- constipation2,705
- neuropathy peripheral2,694
- nausea2,603
- product dose omission issue2,338
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 1,217 |
| 2014 | 2,659 |
| 2015 | 5,383 |
| 2016 | 5,867 |
| 2017 | 6,831 |
| 2018 | 7,077 |
| 2019 | 9,195 |
| 2020 | 10,066 |
| 2021 | 13,133 |
| 2022 | 11,306 |
| 2023 | 8,275 |
| 2024 | 8,960 |
| 2025 | 8,607 |
| 2026 | 5,056 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,950,519 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 8,169 | 53.5 | 52.2 | 333,181 |
| white blood cell count decreasedSignal | 3,709 | 7.2 | 6.9 | 19,057 |
| neuropathy peripheralSignal | 2,694 | 5.9 | 5.7 | 10,660 |
| neutropeniaSignal | 3,391 | 5.2 | 5.0 | 11,174 |
| pneumoniaSignal | 6,387 | 4.1 | 4.0 | 14,686 |
| constipationSignal | 2,705 | 2.5 | 2.4 | 2,510 |
| fatigue | 7,599 | 2.0 | 1.9 | 3,850 |
| death | 7,797 | 1.8 | 1.8 | 3,113 |
| product dose omission issue | 2,338 | 1.6 | 1.6 | 555 |
| asthenia | 2,718 | 1.5 | 1.4 | 413 |
| rash | 3,107 | 1.4 | 1.4 | 439 |
| diarrhoea | 3,966 | 1.2 | 1.2 | 201 |
| off label use | 4,625 | 1.1 | 1.0 | 23 |
| dyspnoea | 2,887 | 1.0 | 1.0 | 3 |
| nausea | 2,603 | 0.7 | 0.6 | 450 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.